Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Techne (TECH) Research & Development (2016 - 2025)

Bio-Techne has reported Research & Development over the past 17 years, most recently at $23.1 million for Q4 2025.

  • Quarterly results put Research & Development at $23.1 million for Q4 2025, down 7.56% from a year ago — trailing twelve months through Dec 2025 was $98.0 million (down 0.67% YoY), and the annual figure for FY2025 was $99.5 million, up 2.93%.
  • Research & Development for Q4 2025 was $23.1 million at Bio-Techne, down from $24.2 million in the prior quarter.
  • Over the last five years, Research & Development for TECH hit a ceiling of $26.0 million in Q2 2025 and a floor of $17.1 million in Q1 2021.
  • Median Research & Development over the past 5 years was $23.3 million (2022), compared with a mean of $23.0 million.
  • Biggest five-year swings in Research & Development: surged 34.65% in 2021 and later dropped 7.56% in 2025.
  • Bio-Techne's Research & Development stood at $20.6 million in 2021, then grew by 8.76% to $22.5 million in 2022, then increased by 2.03% to $22.9 million in 2023, then increased by 9.16% to $25.0 million in 2024, then dropped by 7.56% to $23.1 million in 2025.
  • The last three reported values for Research & Development were $23.1 million (Q4 2025), $24.2 million (Q3 2025), and $26.0 million (Q2 2025) per Business Quant data.